Skip to main content
Clinical Trials/NCT04282551
NCT04282551
Unknown
Not Applicable

The Effect of Oligosaccharides Versus a Placebo on Bowel Habits in Children With Functional Constipation

Wageningen University and Research1 site in 1 country198 target enrollmentJune 24, 2020

Overview

Phase
Not Applicable
Intervention
Not specified
Conditions
Functional Constipation
Sponsor
Wageningen University and Research
Enrollment
198
Locations
1
Primary Endpoint
Stool consistency
Last Updated
4 years ago

Overview

Brief Summary

In the present randomised double blind controlled study, the investigators will study the effects of oligosaccharides vs a placebo on the change in stool consistency and stool frequency in children with functional constipation.

Detailed Description

Functional constipation (FC) in children is a common gastrointestinal (GI) disorder with a worldwide prevalence ranging from 0.7% to 29.6%. Complaints include infrequent bowel movement, painful defecation due to hard and/or large stools, fecal incontinence, and abdominal pain. Although the condition is rarely life-threatening, it strongly impairs quality of life. Oligosaccharides have been shown to relieve constipation symptoms in young adults and elderly. However, sufficient evidence is lacking linking oligosaccharides intake to improve symptoms in children with FC. The investigators hypothesize that oligosaccharides might be able to relieve symptoms of constipation in young children as well, among which softening stools.

Registry
clinicaltrials.gov
Start Date
June 24, 2020
End Date
November 2022
Last Updated
4 years ago
Study Type
Interventional
Study Design
Parallel
Sex
All

Investigators

Responsible Party
Principal Investigator
Principal Investigator

Clara Belzer

Associate Professor

Wageningen University and Research

Eligibility Criteria

Inclusion Criteria

  • Not provided

Exclusion Criteria

  • A potential subject who meets any of the following criteria will be excluded from participation in this study:
  • Children who suffer from any other GI complaints than functional constipation, known structural GI abnormalities, or previous GI surgery
  • Any condition that would make it unsafe for the child to participate.
  • Children with clinically significant cardiac, vascular, liver, pulmonary, psychiatric disorders, severe renal insufficiency, human immunodeficiency virus, acquired immunodeficiency syndrome, hepatitis B or C or known abnormalities of haematology, urinalysis, or blood biochemistry
  • Children who are allergic to cow's milk or fish
  • Use of antibiotics or other medicines or food supplements, and breast milk-feeding, 4 weeks prior to the study, except for the allowed escape medication
  • Children that participate in another clinical trial

Outcomes

Primary Outcomes

Stool consistency

Time Frame: Stool consistency will be measured at different time points during a study period of 13 weeks.

Change in stool consistency measured by the a stool questionnaire; 5 points stool scale from 1 hard to 5 watery (modified Bristol Stool Form Scale)

Secondary Outcomes

  • Stool consistency in number of cases (%)(These outcome measures will be measured at different time point during a study period of 13 weeks.)
  • Stool frequency in number of cases (%)(These outcome measures will be measured at different time point during a study period of 13 weeks.)

Study Sites (1)

Loading locations...

Similar Trials